Drug Pipeline

BL-M11D1 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
1
Recruiting
1
Phase 3
2
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-28 NCT06714591
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1		 Trial sites expanded: 14 -> 18 locations
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-05-15 NCT07591168 A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic Syndromes Phase 1/2 Not Yet Recruiting
Active Studies by Phase
Phase 2/3
1
Phase 1/2
1
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 2/3
NCT07255872 A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax +… Acute Myeloid Leukemia Not Yet Recruiting
Phase 1/2
NCT07591168 A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic Syndromes Myelodysplastic Syndromes Not Yet Recruiting
Phase 1
NCT06714591 Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1 Relapsed/Refractory Acute Myeloid Leukemia Recruiting
Sponsors Running BL-M11D1 Trials
Sichuan Baili Pharmaceutical Co., Ltd. (2) SystImmune Inc. (1)
Disease Areas
Leukemia (2) Acute Myeloid Leukemia (AML) (2) Myelodysplastic Syndromes (MDS) (1)
Get alerts when BL-M11D1 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free